Lonza Group AG stock (CH0013841017): Is biopharma contract demand strong enough to drive sustained u

FierceBiotechAs Akeso takes center stage at ASCO, China biotech industry cements its coming of age

FierceBiotechIMU Biosciences nabs $53M funding round to ‘decode’ the immune system

10x Genomics NewsDeutsche Bank Adjusts Price Target on 10x Genomics to $30 From $23, Maintains Hold Rating - marketscreener.com

FierceBiotechAscidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases

Endpoints NewsLilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases

BioPharma DiveLilly, Ascidian link up in RNA exon editing pact

CellPlant cell wall-plasma membrane attachments mediate stress resilience through cellulose synthase complexes and remorins

CellExplosive cytotoxicity of ruptoblasts bridges hormone surveillance and immune defense

LabiotechSurge in M&As driven by patent expirations

Thermo FisherThermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate Drug Discovery - BioSpectrum Asia

eLifeHSD17B7 is required for the function of sensory hair cells by regulating cholesterol synthesis

BioPharma DiveCelcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial